8-K: Eyenovia Announces 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance

Eyenovia, Inc. will implement a 1-for-80 reverse stock split to meet Nasdaq's minimum bid price requirement, effective January 31, 2025.

Summary

• Eyenovia, Inc. announced a 1-for-80 reverse stock split of its common stock.
• The reverse stock split was approved by the board of directors on January 28, 2025.
• The reverse stock split will be effective at 4:00 p.m. Eastern Time on January 31, 2025.
• Post-split trading will begin on February 3, 2025, under new CUSIP number 30234E 203.
• The primary reason for the reverse stock split is to regain compliance with the Nasdaq Capital Market's minimum bid price requirement.
• The reverse stock split will reduce the number of outstanding shares from approximately 167.5 million to approximately 2.1 million.
• Fractional shares will not be issued; instead, stockholders will receive cash payments.
• Adjustments will be made to outstanding stock options and warrants, as well as the number of shares issuable under the company's stock incentive plan.
• The reverse stock split will not change the number of authorized shares or the par value of the common stock.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed negatively as it indicates the company's stock price is struggling. While the company aims to regain Nasdaq compliance, the underlying issues affecting the stock price remain a concern.

Positives

• The reverse stock split aims to ensure continued listing on the Nasdaq Capital Market.
• The reverse stock split will affect all stockholders uniformly, maintaining their percentage ownership interests (except for fractional share cash payments).

Negatives

• The reverse stock split is being implemented because the company's stock price is below Nasdaq's minimum bid price requirement, which may indicate underlying financial challenges.

Risks

• The company's ability to regain compliance with Nasdaq listing rules is not guaranteed.
• The reverse stock split could negatively impact investor perception of the company.
• The company faces risks related to clinical development, commercialization, and market acceptance of its products.
• The company's financial resources may not be sufficient to meet debt obligations and continue strategic evaluations.

Future Outlook

The company intends to regain compliance with Nasdaq listing rules through the reverse stock split and continues to evaluate strategic alternatives.

Management Comments

• The reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives.

Industry Context

Reverse stock splits are often used by companies facing delisting from exchanges due to low stock prices. This action is intended to increase the stock price and meet the exchange's minimum requirements.

Comparison to Industry Standards

• Many small-cap pharmaceutical companies facing financial difficulties or regulatory setbacks have used reverse stock splits to maintain exchange listings.
• Comparable companies that have recently undertaken reverse stock splits include those in the biotechnology and medical device sectors facing similar challenges in meeting Nasdaq's minimum bid price requirement.
• The success of a reverse stock split in maintaining listing and improving investor confidence varies widely and depends on the underlying health and future prospects of the company.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, with cash payments for fractional shares.
• The reverse stock split aims to maintain the company's listing on Nasdaq, which could impact investor confidence.
• Employees may be affected by the company's overall financial performance and strategic decisions.

Key Dates